New Year, New Policy Challenges for Pharma
Pricing, safety, comparative effectiveness, patents, and biosimilars top 2008's policy agenda
Lincoln, Digger, and the Rest of the Gang
We asked seven industry experts to talk about today's best (and worst) pharma icons
Oxfam Points Finger
Pharma defends itself against claims made in charity's report on drug access for the world's poor
Beyond the Foggy Supply Chain
More control over warehouse data (from drug company to pharmacist) is key to inventory control
Pharma Forecast: Into the Woods
Pharm Exec asks experts to predict what 2008 has up its sleeve for the industry--from the top line to the bottom line, from R&D to M&As, from Congress to the courts.
Not Enough Science
A new report says FDA is desperately behind on science. At last, a critique we can actually do something about. But will we?
The Essential Essner
The departure of Wyeth's legendary CEO prompts a reflection on true leadership-and cooking
Salesforce Survey 2008
Welcome to the new employer's market for reps. The Hay Group's annual survey reports how, as the primary sales force contracts, so too does its pay.
Outsource from the Inside
When it comes to clinical teams, the question of whether or not to outsource brings some untraditional answers
The Blogosphere: Too Hot for Pharma?
Pharma companies would do well to proceed with extreme caution when entering the blogosphere
R&D: Learning to Share
Novartis' Paul Herrling talks about how Big Pharma can learn from nonprofit R&D and collaborate to get an edge on the drug safety problem.
